J Immunother Cancer 2020]. XmAb18968 is a novel CD38-CD3 bi-specific T-cell engager with Fc domain modified to minimize Fcγ receptor binding and non-selective T-cell activation resulting in reduced ...

they exert T cell-mediated cytotoxicity, which ultimately induces tumor cell death. Currently, there are three CD38/CD3-targeting BiTEs to treat MM – all of which are in phase I clinical trials.

B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children, accounting for around 85% of pediatric ...

The approval targets patients who have undergone a minimum of three previous therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cluster of differentiation 38 (CD38 ...

Through a previously undescribed form of cell auto-signaling, T cells were shown to activate themselves in peripheral tissues, fueling their ability to attack tumors. The study, published May 8 ...

Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1–2 trial involving patients with relapsed myeloma or ...

Cytotoxic or CD8 + T-cells, known for their ability to kill infected and cancer cells, require activation and differentiation within specialized niches of the tumor microenvironment to effectively ...

can result in targeted clearance of CD38-positive cells, including plasma cells. We conducted a phase 1–2, open-label study to evaluate the safety and efficacy of CM313 in adult patients with ITP.